Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response.
MIBIOTIMI
Phase 2 other active
Quick answer
Tumour heterogeneity studies based on dedicated breast PET using proliferation radiotracers: early detection of the treatment response. for Breast cancer is a Phase 2 program (other) at The George Institute with 1 ClinicalTrials.gov record(s).
Program details
- Company
- The George Institute
- Indication
- Breast cancer
- Phase
- Phase 2
- Modality
- other
- Status
- active